TradeUP Acquisition Corp. to liquidate trust account into cash, announces July 31 special meeting for Estrella merger

Estrella Immunopharma, Inc.

Trust account to liquidate U.S. treasury obligations and money market funds on July 14, 2023; proceeds held in cash to avoid Investment Company Act classification.
Proxy statement/prospectus for business combination with Estrella Biopharma declared effective July 11, 2023; special meeting set for July 31, 2023.
Extension meeting on July 17, 2023 to vote on extending combination deadline to July 14, 2024; redemption price ~$10.51/share if extension approved.
Public stockholders may redeem shares at ~$10.51 in connection with extension (deadline July 13) or at expected ~$0.05 higher for merger (deadline July 27).
If extension approved, additional $0.05 per share deposited monthly into trust for each non-redeemed share beyond July 19, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.